Established in 2006, Polgenix, Inc., is a small biotech company, whose aims encompass two areas: 1. Drug discovery targeting G protein-coupled receptors (GPCRs) to treat common blinding diseases, 2. Innovative high-resolution retinal imaging for ophthalmic drug discovery.

Polgenix is cooperating with ICTER on the front of evaluating novel eye diagnostic methods.